Sumitomo Mitsui Trust Holdings, Inc. Alnylam Pharmaceuticals, Inc. Transaction History

Sumitomo Mitsui Trust Holdings, Inc.

$142 Billion
Q3 2024

A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 278,241 shares of ALNY stock, worth $65.5 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

278,241

Previous 276,947 0.47%

Holding current value

$65.5 Million

Previous $67.3 Million 13.73%

% of portfolio

0.05%

Previous 0.05%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$233.81 - $287.01 $302,550 - $371,390	1,294 Added 0.47%	278,241 $76.5 Million
Q2 2024 Jul 19, 2024	SELL	$143.31 - $247.0 $2.01 Million - $3.47 Million	-14,049 Reduced 4.83%	276,947 $67.3 Million
Q1 2024 Apr 19, 2024	SELL	$146.51 - $198.2 $627,502 - $848,890	-4,283 Reduced 1.45%	290,996 $43.5 Million
Q4 2023 Jan 30, 2024	SELL	$151.41 - $196.57 $215,153 - $279,325	-1,421 Reduced 0.48%	295,279 $56.5 Million
Q3 2023 Oct 30, 2023	SELL	$170.77 - $211.65 $329,415 - $408,272	-1,929 Reduced 0.65%	296,700 $52.5 Million
Q2 2023 Jul 31, 2023	SELL	$185.01 - $212.05 $7.83 Million - $8.98 Million	-42,338 Reduced 12.42%	298,629 $56.7 Million
Q1 2023 Apr 27, 2023	BUY	$182.66 - $235.53 $728,996 - $940,000	3,991 Added 1.18%	340,967 $68.3 Million
Q4 2022 Jan 30, 2023	SELL	$185.53 - $241.31 $317,070 - $412,398	-1,709 Reduced 0.5%	336,976 $80.1 Million
Q3 2022 Oct 21, 2022	BUY	$138.54 - $232.0 $116,789 - $195,576	843 Added 0.25%	338,685 $67.8 Million
Q2 2022 Jul 26, 2022	BUY	$120.42 - $169.29 $1.82 Million - $2.56 Million	15,099 Added 4.68%	337,842 $49.3 Million
Q1 2022 Apr 27, 2022	SELL	$127.18 - $173.91 $217,350 - $297,212	-1,709 Reduced 0.53%	322,743 $52.7 Million
Q4 2021 Feb 02, 2022	SELL	$159.56 - $209.29 $1.3 Million - $1.7 Million	-8,119 Reduced 2.44%	324,452 $55 Million
Q3 2021 Oct 25, 2021	SELL	$169.75 - $207.73 $2.6 Million - $3.19 Million	-15,344 Reduced 4.41%	332,571 $62.8 Million
Q2 2021 Aug 02, 2021	SELL	$128.63 - $176.89 $2.89 Million - $3.97 Million	-22,469 Reduced 6.07%	347,915 $59 Million
Q1 2021 Apr 30, 2021	SELL	$126.83 - $175.69 $1.4 Million - $1.94 Million	-11,027 Reduced 2.89%	370,384 $52.3 Million
Q4 2020 Feb 05, 2021	SELL	$122.97 - $147.0 $7.54 Million - $9.01 Million	-61,284 Reduced 13.84%	381,411 $49.6 Million
Q3 2020 Oct 30, 2020	SELL	$121.19 - $165.49 $14.1 Million - $19.3 Million	-116,349 Reduced 20.81%	442,695 $64.5 Million
Q2 2020 Jul 27, 2020	SELL	$104.21 - $156.44 $17.8 Million - $26.7 Million	-170,925 Reduced 23.42%	559,044 $82.8 Million
Q1 2020 Apr 27, 2020	BUY	$93.12 - $133.99 $26.7 Million - $38.4 Million	286,933 Added 64.77%	729,969 $79.5 Million
Q4 2019 Jan 31, 2020	BUY	$74.51 - $124.23 $641,009 - $1.07 Million	8,603 Added 1.98%	443,036 $51 Million
Q3 2019 Oct 31, 2019	BUY	$70.9 - $87.82 $6.13 Million - $7.59 Million	86,454 Added 24.84%	434,433 $34.9 Million
Q2 2019 Jul 29, 2019	SELL	$65.86 - $92.79 $199,819 - $281,524	-3,034 Reduced 0.86%	347,979 $25.2 Million
Q1 2019 May 08, 2019	BUY	$72.76 - $93.45 $2.29 Million - $2.94 Million	31,459 Added 9.84%	351,013 $32.8 Million
Q4 2018 Feb 06, 2019	BUY	$62.67 - $88.33 $3.27 Million - $4.6 Million	52,110 Added 19.48%	319,554 $22.5 Million
Q3 2018 Nov 07, 2018	SELL	$87.52 - $122.67 $337,039 - $472,402	-3,851 Reduced 1.42%	267,444 $23.4 Million
Q2 2018 Aug 01, 2018	BUY	$88.31 - $107.8 $1.42 Million - $1.74 Million	16,110 Added 6.31%	271,295 $26.7 Million
Q1 2018 May 01, 2018	BUY	$115.92 - $148.54 $1.78 Million - $2.28 Million	15,369 Added 6.41%	255,185 $30.4 Million
Q4 2017 Feb 06, 2018	BUY	$114.49 - $139.98 $27.5 Million - $33.6 Million	239,816	239,816 $30.5 Million

Others Institutions Holding ALNY

# of Institutions

641

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.

Account

Sumitomo Mitsui Trust Holdings, Inc. Alnylam Pharmaceuticals, Inc. Transaction History